3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Breast Neoplasms
545
Lymphoma
444
Precursor Cell Lymphoblastic Leukemia-Lymphoma
409
Lymphoma, Large B-Cell, Diffuse
347
Leukemia
344
Multiple Myeloma
335
Lymphoma, Non-Hodgkin
316
Leukemia, Myeloid, Acute
288
Leukemia, Lymphocytic, Chronic, B-Cell
285
Lymphoma, Follicular
240
Burkitt Lymphoma
217
Myelodysplastic Syndromes
209
Lymphoma, Mantle-Cell
201
Hodgkin Disease
193
Recurrence
153
Lymphoma, B-Cell, Marginal Zone
142
Melanoma
135
Lymphoma, Large-Cell, Immunoblastic
116
Neoplasms
109
Lymphoma, B-Cell
103
Neuroblastoma
101
Neoplasms, Plasma Cell
99
Ovarian Neoplasms
96
Triple Negative Breast Neoplasms
93
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
91
Myeloproliferative Disorders
87
Hematologic Neoplasms
87
Leukemia, Myeloid, Chronic-Phase
83
Leukemia, Myeloid, Accelerated Phase
80
Leukemia, Myelomonocytic, Chronic
78
Interventions
trametinib
2
dabrafenib
2
mirdametinib
1
antineoplaston AS 2-1
1
antineoplaston A10
1
Vincristine
1
Irinotecan
1
Cyclophosphamide
1
Carboplatin
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Ganglioglioma
×
Cyclophosphamide
×
Clear all
NCT03152318
2026-03-04
rQNestin
Dana-Farber Cancer Institute
Phase 1
Active not recruiting
62 enrolled